Physician profile
Mosab A Frefer
NPI 1659800977
$830.21
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $200 · 2022: $157 · 2023: $268 · 2024: $205.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $473.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $472.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $106.04 | 2021-2024 | Lokelma, Farxiga, Airsupra |
| Amgen INC. | $83.65 | 2021-2024 | Repatha, Otezla |
| Abbvie INC. | $82.00 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $67.03 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $64.25 | 2021-2022 | |
| Abbott Laboratories | $62.02 | 2022-2024 | Freestyle Libre 3 |
| Lundbeck LLC | $57.38 | 2023-2024 | Rexulti |
| Novartis Pharmaceuticals Corporation | $44.22 | 2023 | |
| Collegium Pharmaceutical, INC. | $30.97 | 2022-2023 | Belbuca |
| Bardy Diagnostics, INC. | $29.80 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $29.74 | 2024 | Abilify Maintena, Rexulti |
| Teva Pharmaceuticals USA, INC. | $22.40 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.44 | 2023 | Trulance, Xifaxan |
| Dexcom, INC. | $20.43 | 2021 | |
| Idorsia Pharmaceuticals US INC | $18.82 | 2023 | Quviviq |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $17.56 | 2023 | |
| Novo Nordisk INC | $15.37 | 2021 | |
| Glaxosmithkline, LLC. | $15.19 | 2023 | Arexvy, Shingrix |
| Boston Scientific Corporation | $14.80 | 2021 | |
| Janssen Pharmaceuticals, INC | $14.69 | 2021 | |
| Exact Sciences Corporation | $13.41 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mosab Frefer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.